How this instrument works
The 4Ts score sums four categories, each worth 0, 1, or 2 points: Thrombocytopenia, the degree of platelet fall; Timing, whether that fall fits the pattern typically seen with heparin exposure; Thrombosis, whether a new clot or other sequela has occurred; and oTher causes, whether anything besides heparin plausibly explains the falling platelet count. The total spans 0 to 8, and the fourth category is worth reading twice — it's scored in reverse from what people usually expect, with 2 points meaning no other cause is apparent and 0 points meaning a definite alternative explanation exists.
The reason this bedside score exists at all comes down to timing. Laboratory assays that actually confirm heparin-induced thrombocytopenia are comparatively slow and aren't always available around the clock, while a patient with a falling platelet count and a new clot can't safely wait for that result before a decision gets made. A high 4Ts total is often enough on its own to justify stopping heparin immediately and switching empirically to a non-heparin anticoagulant while confirmatory testing is still pending — because untreated heparin-induced thrombocytopenia with thrombosis is dangerous enough that waiting for lab confirmation carries its own real risk.
The score's best-documented strength sits at the opposite end from where people usually look. A low 4Ts total has a very high negative predictive value — in pooled data across multiple studies, a low-probability score reliably ruled the condition out, correctly identifying people who did not have it in the overwhelming majority of cases. That's arguably the single most clinically useful fact about this instrument: it is much better at telling you who almost certainly doesn't have the condition than at nailing down a precise probability for who does.
- Score Thrombocytopenia from 0 (platelet fall under 30%, or nadir below 10) to 2 (fall over 50%, with a nadir at or above 20).
- Score Timing from 0 (the fall doesn't fit, with no recent heparin exposure) to 2 (a clear fall on days 5 to 10, or within a day given recent prior heparin exposure).
- Score Thrombosis from 0 (none) to 2 (a new clot, skin necrosis, or an acute systemic reaction after heparin).
- Score oTher causes in reverse of the other three: 2 if nothing else plausibly explains the platelet fall, 1 if another cause is possible, 0 if another cause is definite.
- Read the total and its band; the working block sums all four categories so you can see exactly which one is driving the result.
Worked example — a high-probability presentation
A patient's platelet count has fallen more than 50%, with a nadir of 25 (2 points). The drop began on day 7 of heparin therapy, a textbook fit for the typical pattern (2). A new deep vein thrombosis was diagnosed the same week (2). Reviewing the chart, there's a plausible but not definite alternative explanation for the platelet fall, like recent sepsis, so oTher causes scores 1. Summing the four: 2+2+2+1 = 7, landing in the 6-8 high-probability band, enough on its own to justify stopping heparin and starting a non-heparin anticoagulant while lab confirmation is pending.
Contrast a lower-risk case: a modest 30-50% platelet fall with a nadir of 15 (1 point), a somewhat unclear timing pattern (1), no thrombosis at all (0), and a possible other cause (1). That totals 1+1+0+1 = 3, in the 0-3 low-probability band — the range where this score's negative predictive value is strongest and confirmatory testing carries the least urgency.
Questions
Why is the oTher causes category scored backwards from the others?
Because it's measuring the absence of an alternative explanation, not the presence of a finding. A high score there — 2 points — means nothing else plausibly explains the platelet fall, which actually raises suspicion for heparin-induced thrombocytopenia. A definite alternative cause, like a recent infection known to drop platelets, scores 0 and pulls the total down, since it makes heparin a less likely culprit.
What do the 4Ts score bands mean?
A total of 0 to 3 is read as low probability, 4 to 5 as intermediate, and 6 to 8 as high probability. These bands come from the original 2006 validation by Lo and colleagues and have held up reasonably well across subsequent studies, though intermediate scores in particular still leave real diagnostic uncertainty that usually calls for laboratory testing rather than a decision based on the bedside score alone.
Can a high 4Ts score alone justify stopping heparin before lab results come back?
In practice, often yes. Because confirmatory antibody assays are comparatively slow and heparin-induced thrombocytopenia with thrombosis is a genuinely dangerous complication, many clinicians treat a high pretest probability score as sufficient reason to stop heparin and start a non-heparin anticoagulant empirically, without waiting for the lab result — accepting the cost of unnecessary treatment in some cases as the safer trade-off against missing a true case.
What is the 4Ts score actually best at — ruling in or ruling out?
Ruling out. Pooled results across multiple validation studies show a low-probability score has a very high negative predictive value, correctly identifying people who don't have the condition in the great majority of cases. Performance at the higher end is weaker and more variable between clinical settings, which is why an intermediate or high score is usually treated as a reason to test rather than as confirmation on its own.
Who developed the 4Ts score?
Lo, Juhl, Warkentin, Sigouin, Eichler, and Greinacher published it in the Journal of Thrombosis and Haemostasis in 2006, evaluating the pretest clinical score across two different clinical settings to see how well four simple bedside criteria could predict a laboratory-confirmed diagnosis.
Is this tool meant for patients to use on their own?
No. Scoring the four categories accurately requires clinical judgment about platelet trends, exposure timing, and other possible causes of thrombocytopenia — information generally available to a treating clinician reviewing a chart, not something a patient can assess unassisted. This is a bedside reference for trained clinical use, not a self-diagnosis instrument.
References
- Lo et al., 2006, J Thromb Haemost — original 4Ts validation (PubMed)
- Cuker et al., 2012, Blood — systematic review and meta-analysis of 4Ts predictive value (PubMed)
Read this first: This instrument computes a screening figure from population formulas — it is not a diagnosis, and it cannot see the whole picture a clinician can. Use it to inform a conversation, not to replace one.